CurrentUnitedHealthcarePolicy CS169KS.03

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea (for Kansas Only)

UnitedHealthcare Community Plan medical policy for Kansas governing coverage and medical necessity criteria for multiplex PCR gastrointestinal pathogen panels (up to specified target counts) for evaluation of infectious diarrhea, including required clinical indications and exclusions.

Policy Summary

PayerUnitedHealthcare

PolicyGastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea (for Kansas Only)

Policy CodePolicy CS169KS.03

Change TypeNo material change

Effective DateMar 1, 2026

Next Review Date

Key ActionEnsure the patient medical record contains documentation supporting medical necessity, including history, physical exam, and diagnostic test results, as documentation may be requested for review.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes were made in this update.

2Covered panel size tiers (3-5, 6-11 targets)

1Not covered: >11 targets

KansasState-specific applicability

Coverage Summary

Scope: This policy (Policy Number CS169KS.03) is the UnitedHealthcare Community Plan medical policy for Kansas only governing coverage and medical necessity criteria for multiplex PCR gastrointestinal pathogen panels used to evaluate infectious diarrhea.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Key thresholds summary: Panel target count threshold — testing with panels of up to 5 targets is covered when performed with blood cultures under specified indications; panels of up to 11 targets are covered for evaluation of persistent diarrhea with specified risk factors; panels of greater than 11 targets are not medically necessary. Duration of diarrhea threshold — testing criteria include diarrhea lasting more than 7 days (persistent diarrhea).

Provider Actions / Prior Authorization

Documentation Required

Medical record documentation required

The patient's medical record must contain documentation that fully supports medical necessity for the requested gastrointestinal multiplex PCR testing. Documentation may be requested for review and should include relevant history, physical examination findings, and results of pertinent diagnostic tests or procedures to demonstrate that clinical criteria are met.

supporting history, physical exam, diagnostic test results

Prior Authorization

Coverage contingent on clinical criteria

Coverage is contingent on the testing meeting the policy's clinical indications (for example: duration of diarrhea, presence of fever, bloody or mucoid stools, severe abdominal cramping/tenderness, signs of sepsis, immunosuppression, or travel history). Claims may be reviewed against these criteria and denied if the clinical indications are not met. Policy coverage differs by panel size: panels up to 5 targets and panels up to 11 targets are covered in specific clinical situations, whereas panels with more than 11 targets are considered not medically necessary.

Affected panel sizes: up to 5 targets; up to 11 targets; >11 targets not covered

Background & Evidence

Background: Multiplex PCR gastrointestinal pathogen panels are described for clinical contexts where they can improve detection and shorten time-to-result compared with conventional testing — particularly in moderate-to-severe, bloody, febrile, nosocomial, or persistent diarrhea and in immunocompromised patients. Advantages include higher sensitivity and faster turnaround that can enable earlier organism-level identification and influence infection control and antimicrobial decisions. Limitations noted in the policy include lack of antibiotic susceptibility data from molecular panels, variable panel composition (some targets may be absent or rarely detected), and the potential to detect carriage or nonviable organisms that complicate result interpretation. This policy and these considerations apply specifically to Kansas.

Evidence summary: Systematic reviews and primary studies (e.g., Patel 2024; López Muñoz 2024) and trials/cohort studies (including Xie 2023) demonstrate that multiplex PCR panels have consistently high diagnostic sensitivity and specificity and reduce time-to-result versus conventional methods, but evidence is mixed regarding improvement in clinical outcomes; some studies show impacts on management or resource use while randomized data (e.g., Xie 2023) show limited effect on clinical outcomes.

Definitions

Thresholds